How CRISPR and functional genomics are used to establish causality, understand disease mechanisms and guide early drug ...
CRISPR Therapeutics reports promising Phase 1 clinical data for CTX310™, with significant triglyceride and LDL reductions, and updates on other programs. CRISPR Therapeutics announced promising new ...
CRISPR Therapeutics AG (NASDAQ:CRSP) reported new topline study results on Wednesday to establish risk factors for atherosclerotic heart disease. The company disclosed data regarding the first 10 ...
-New Phase 1 clinical data for CTX310™ continues to demonstrate dose-dependent reductions in triglycerides (TG) and low-density lipoprotein (LDL), with peak reduction of up to 82% in TG and up to 86% ...
-Data presented in a late-breaking presentation at the American Heart Association (AHA) Scientific Sessions 2025- -Phase 1 clinical data for CTX310® demonstrate robust, dose-dependent reductions in ...
FAYETTEVILLE, GA, UNITED STATES, January 15, 2026 /EINPresswire.com/ -- Understanding why cancer cells rely on specific ...
ALAMEDA, Calif.--(BUSINESS WIRE)--Scribe Therapeutics Inc. (“Scribe”), a genetic medicines company pioneering next-generation in vivo CRISPR-based medicines designed to be safe, durable, and effective ...
“CRISPR Therapeutics remains focused on executing our strategic priorities and advancing our portfolio of innovative therapies. We are highly encouraged by the initial data from our Phase 1 trial for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results